Abstract
Although generally well tolerated, statin users frequently report muscle-related side effects, ranging from self-limiting myalgias to rhabdomyolysis or the rare clinical entity of statin-associated immune-mediated necrotizing myopathy (IMNM). Statin-associated IMNM is based on the development of autoantibodies against 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme in cholesterol synthesis and the pharmacologic target of statins, and leads to a necrotizing myopathy requiring immunosuppressive therapy. This review attempts to recapitulate the diverse aspects of anti-HMGCR IMNM, including clinical presenta-tion, diagnostic modalities, genetic risk associations, therapeutic options and potential pathoge-netic pathways.
Original language | English (US) |
---|---|
Pages (from-to) | 483-492 |
Number of pages | 10 |
Journal | Therapeutics and Clinical Risk Management |
Volume | 16 |
DOIs | |
State | Published - 2020 |
Externally published | Yes |
Keywords
- Anti-HMGCR
- Myopathy
- Stains
- Statin myopathy
- Statin toxicity
ASJC Scopus subject areas
- Safety Research
- Pharmacology, Toxicology and Pharmaceutics(all)
- Pharmacology (medical)
- Chemical Health and Safety